T2 Biosystems, Inc.

Equities

TTOO

US89853L3024

Advanced Medical Equipment & Technology

Real-time Estimate Cboe BZX Other stock markets 02:24:01 2024-04-16 pm EDT			5-day change	1st Jan Change
3.04 ^USD	+2.36%		-2.56%	-51.39%

Apr. 01	T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 28	T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc	CI

T2 Biosystems, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 16, 2022 at 06:14 am EDT

T2 Biosystems, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported revenue was USD 5.91 million compared to USD 6.69 million a year ago. Net loss was USD 18.03 million compared to USD 12.48 million a year ago. Basic loss per share from continuing operations was USD 5 compared to USD 4 a year ago. Diluted loss per share from continuing operations was USD 5 compared to USD 4 a year ago.
For the six months, revenue was USD 13.15 million compared to USD 13.65 million a year ago. Net loss was USD 34.53 million compared to USD 23.14 million a year ago. Basic loss per share from continuing operations was USD 10 compared to USD 7.5 a year ago. Diluted loss per share from continuing operations was USD 10 compared to USD 7.5 a year ago.

Latest news about T2 Biosystems, Inc.

T2 Biosystems, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc	Mar. 28	CI
T2 Biosystems, Inc. Reiterates Revenue Guidance for the Year 2024	Mar. 20	CI
Transcript : T2 Biosystems, Inc. - Special Call	Mar. 20
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates	Mar. 20	CI
T2 Biosystems, Inc. Announces Publication of New Study Highlighting Clinical Benefits and Performance of Real-World Use of T2Resistance Panel in Journal of Clinical Microbiology	Mar. 18	CI
Transcript : T2 Biosystems, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
T2 Biosystems, Inc. Announces Commercial Expansion Through Distributors in Europe and Asia	Feb. 15	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	Feb. 12	MT
Sector Update: Health Care Stocks Steady in Afternoon Trading	Feb. 12	MT
T2 Biosystems Gets FDA Clearance for Expanded T2Bacteria Panel; Shares Rise	Feb. 12	MT
T2 Biosystems Gets 510(k) Clearance For Expanded T2Bacteria Panel	Feb. 12	DJ
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel	Feb. 12	CI
T2 Biosystems Announces Participation in NIH-Funded Antibacterial Resistance Leadership Group Pilot Study for Pneumonia Patients	Jan. 18	CI
T2 Biosystems, Inc. Announces the Resignation of Thierry Bernard as Class II Director and All Committees of the Board of Directors	Jan. 05	CI
T2 Biosystems, Inc. Announces FDA 510(K) Submission to Expand Use of the FDA-Cleared T2candida Panel to Include Pediatric Testing	Jan. 03	CI
T2 Biosystems, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 15	CI
T2 Biosystems, Inc. Highlights New Clinical Data Presented At IDWeek 2023 Conference	23-10-24	CI
T2 Biosystems, Inc. Announces Amendment and Extension of CRG Term Loan Agreement	23-10-23	CI
T2 Biosystems Submits 510(k) to Add Detection of Acinetobacter Baumannii to List of Pathogens Covered by T2Bacteria Panel	23-10-12	MT
Transcript : T2 Biosystems, Inc., Q3 2023 Earnings Call, Oct 12, 2023	23-10-12
Sector Update: Health Care Stocks Decline in Late Afternoon	23-10-12	MT
Top Midday Decliners	23-10-12	MT
Sector Update: Health Care Stocks Lower Thursday Afternoon	23-10-12	MT
T2 Biosystems Announces 1-for-100 Reverse Stock Split; Shares Fall	23-10-12	MT

Chart T2 Biosystems, Inc.

Duration

Period

More charts

Company Profile

T2 Biosystems, Inc. is an in-vitro diagnostics company. The Company is focused on the detection of sepsis-causing pathogens and antibiotic resistance genes. The Company is using its T2MR technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its primary commercial products include the T2Candida Panel and the T2Bacteria Panel. Its T2Candida Panel is a direct-from-blood test that identifies the lethal form of common bloodstream infections that cause sepsis and candidemia. Its T2Bacteria Panel is a direct-from-blood test that detects certain bacterial pathogens associated with sepsis. Its primary commercial products also include the T2Dx Instrument, the T2Resistance Panel, and the T2SARS-CoV-2 Panel.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-05-01 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
T2 BIOSYSTEMS, INC.	-51.39%	16.37M
THERMO FISHER SCIENTIFIC	+4.78%	213B
DANAHER CORPORATION	+4.28%	177B
INTUITIVE SURGICAL, INC.	+13.56%	134B
BOSTON SCIENTIFIC CORPORATION	+18.70%	99.13B
SIEMENS HEALTHINEERS AG	+0.11%	63.47B
EDWARDS LIFESCIENCES CORPORATION	+18.05%	53.69B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-4.51%	46.36B
AGILENT TECHNOLOGIES, INC.	-0.89%	41.09B
GE HEALTHCARE TECHNOLOGIES INC.	+11.39%	39.3B

Other Advanced Medical Equipment & Technology